{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:53:59Z","timestamp":1791028439630,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejim.2026.107219","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:18:17Z","timestamp":1791026297000},"page":"107219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis"],"prefix":"10.1016","author":[{"given":"Eirini I.","family":"Rigopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Lygoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1914-150X","authenticated-orcid":false,"given":"Konstantinos","family":"Papantoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4779-8155","authenticated-orcid":false,"given":"Stella","family":"Gabeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Samakidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafni","family":"Sveroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Giannoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-8640","authenticated-orcid":false,"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Zachou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-8464","authenticated-orcid":false,"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2026.107219_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ejim.2026.107219_bib0002","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","article-title":"Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC","volume":"78","author":"Sharpton","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0003","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population- based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2026.107219_bib0005","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2026.107219_bib0006","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2026.107219_bib0007","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejim.2026.107219_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2026.107219_bib0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fphys.2013.00195","article-title":"Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats","volume":"4","author":"Schierwagen","year":"2013","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejim.2026.107219_bib0012","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2026.107219_bib0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0014","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2026.107219_bib0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0016","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population- based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C","volume":"62","author":"Simon","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0019","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection","volume":"63","author":"Yang","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ejim.2026.107219_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.017","article-title":"Statins are associated with a decreased risk of severe liver disease in invididuals with noncirrhotic chronic liver disease","volume":"22","author":"Sharma","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ejim.2026.107219_bib0022","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/hep4.2022","article-title":"Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study","volume":"6","author":"Yun","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejim.2026.107219_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s44355-025-00020-4","article-title":"Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies","volume":"2","author":"Ruan","year":"2025","journal-title":"npj Gut Liver"},{"issue":"6","key":"10.1016\/j.ejim.2026.107219_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20222","article-title":"Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality","volume":"6","author":"Vell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2026.107219_bib0026","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review","volume":"194","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ejim.2026.107219_bib0027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejim.2026.107219_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MCG.0000000000000029","article-title":"Metabolic syndrome associated with primary biliary cirrhosis","volume":"49","author":"Floreani","year":"2015","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejim.2026.107219_bib0029","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ejim.2026.107219_bib0030","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cgh.2018.04.023","article-title":"Treatment of dyslipidemia in common liver diseases","volume":"16","author":"Speliotes","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ejim.2026.107219_bib0031","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis","volume":"33","author":"Cash","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2026.107219_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001701","article-title":"Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study","author":"Choi","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107219_bib0033","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2026.107219_bib0034","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17530059.2.6.621","article-title":"Molecular diagnostics of primary biliary cirrhosis","volume":"2","author":"Rigopoulou","year":"2008","journal-title":"Expert Opin Med Diagn"},{"issue":"9","key":"10.1016\/j.ejim.2026.107219_bib0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2016.1217159","article-title":"Molecular diagnostic testing for primary biliary cholangitis","volume":"16","author":"Gatselis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"10.1016\/j.ejim.2026.107219_bib0036","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00005-019-00550-9","article-title":"Variant and specific forms of autoimmune cholestatic liver diseases","volume":"67","author":"Dalekos","year":"2019","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"2","key":"10.1016\/j.ejim.2026.107219_bib0037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"6","key":"10.1016\/j.ejim.2026.107219_bib0038","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Global & ERN Rare-Liver PBC Study Groups. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ejim.2026.107219_bib0039","first-page":"123","article-title":"Hellenic Autoimmune Liver Diseases Study Group. Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis","volume":"39","author":"Dalekos","year":"2026","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejim.2026.107219_bib0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.ejim.2026.107219_bib0041","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2026.107219_bib0042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2017.05.006","article-title":"Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece","volume":"42","author":"Gatselis","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.107219_bib0043","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107219_bib0044","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hjc.2023.10.001","article-title":"Prediction of 10-year cardiovascular disease risk by diabetes status and lipoprotein-a levels; the HellenicSCORE II","volume":"79","author":"Panagiotakos","year":"2024","journal-title":"Hellenic J Cardiol"},{"issue":"25","key":"10.1016\/j.ejim.2026.107219_bib0045","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107219_bib0046","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/HEP.0000000000001722","article-title":"Statins in primary biliary cholangitis: Untangling promise from bias","volume":"84","author":"Bittermann","year":"2026","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2026.107219_bib0047","article-title":"Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure","volume":"5","author":"Chapin","year":"2023","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.ejim.2026.107219_bib0048","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","article-title":"Statin use and risks of hepatocellular carcinoma and liver fibrosis in chronic liver disease","volume":"185","author":"Choi","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.107219_bib0049","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cancers13051023","article-title":"Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases","volume":"13","author":"Rigopoulou","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:18:23Z","timestamp":1791026303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526005248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"alternative-id":["S0953620526005248"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107219","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107219"}}